

## **Wockhardt wins Government of India Patent Award**

### **70 Patents Granted: 15 Indian and 55 International**

**Mumbai, September 24, 2009**

Pharmaceutical and Biotechnology major Wockhardt Limited has received a very prestigious award instituted by the Government of India as the 'Pharmaceutical Company for the maximum number of Patent filings and grants from India.' Wockhardt has been granted 70 patents, 15 from the Indian Patent office and 55 from the American and European Patent offices. Shri Anand Sharma, Hon'ble Minister for Commerce & Industry, will present the award on 25<sup>th</sup> September 2009 in Hyderabad.

Speaking on this momentous occasion, Wockhardt Chairman Habil Khorakiwala said, "This award is a recognition of Wockhardt's robust, resilient and uncompromising intellectual pursuit in discovering new ways and methods of medical innovation." He further stated, "this also recognises the efforts of over 500 scientists working in our Research and Development centres involved in the research of Biotechnology, New Drug Discovery, New Technology in Pharmaceutical and Medicinal chemistry."

Wockhardt with its dedicated Global IP team has demonstrated a high calibre of R&D and intellectual prowess globally. A noteworthy aspect of Wockhardt's R&D, which is unique to any single organisation in India, is its multifaceted research capabilities in the areas of New Drug Discovery (NDD), Biotech & Genomics Research, Chemical Research, Pharma Research, Clinical Research and Devices Development.

#### **About Wockhardt**

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.